6 Degrees is a full-service public relations firm that specializes in serving the life sciences industry. Led by principal, @MediaMinder.
Joined March 2011
- Tweets3.1K
- Following419
- Followers274
- Likes75
🎉Congrats to #client @IncyclixBio on joining @FierceBiotech’s Fierce 15 biotechnology companies of 2025 🎉
Incyclix is being recognized for its innovative #CDK2 inhibitor targeting advanced and resistant breast & ovarian cancers. fiercehealthcare.com/special…
Honored to be named one of @FierceBiotech #Fierce15 '25!
At Incyclix, we’re advancing a potent, selective #CDK2 inhibitor for advanced & treatment-resistant cancers—always with patients at the center of our mission. Thanks to Fierce for this recognition! incyclixbio.com/news_release…
Thanks to our #client and their #CART #celltherapy, Julia Pallentino, diagnosed with #MultipleMyeloma, is ~2 years cancer-free. Incredible patients like her keep us inspired to serve our life science #clients as they advance innovations. 💪 wtxl.com/northeast-tallahass…
What are the latest developments in whole eye transplantation? Our #client, @FightBlindness, shares exciting insights in their recent interview with @lmgbio's The Bio Report! 🎧 Listen here ⬇️ thebioreport.podbean.com/e/m… #blindness
Proud to support innovators like our #client @IncyclixBio which received @FDA Fast Track designation for its investigational #CDK2 inhibitor, INX-315, to treat CCNE1-amplified, platinum-resistant/refractory #ovariancancer — a critical unmet need. 🔗 incyclixbiostg.wpengine.com/…
#NEWS: The @US_FDA has granted Fast Track designation for INX-315, our investigational #CDK2 inhibitor, for the treatment of patients with CCNE1-amplified platinum-resistant/refractory #ovariancancer. incyclixbiostg.wpengine.com/…
📣 We’re thrilled to share that Gina Mangiaracina has been promoted to Chief Operating Officer! 📣 Her leadership, strategic mind, exceptional communication skills and unwavering commitment to our #lifesciences clients has been a driving force behind our growth.
Congrats, Gina!🎉
Fueling early-stage biotech innovation has been a driving force of Dr. Ned Sharpless’ (@nes047) career. Now the former NCI director is leveraging his expertise to power groundbreaking science with Jupiter BioVentures (#client). 🔗@TriangleBIZJrnl ⬇️ bizjournals.com/triangle/new…
🏆🏀 Huge congrats to the winners of our #MarchMadness Bracket Challenge! 🏀🏆
Big thanks to everyone for joining the fun. The competition was tough!
🎉 Our top three players win charitable donations to their chosen causes:
1️⃣ Chris Licata
2️⃣ Rick Sauter
3️⃣ Chris Bowe
Our client @LegendBiotech is a leader in CAR-T bioprocessing. Learn more about how the Company adopts new technology to continuously improve manufacturing of its commercial #celltherapy products in @_CellandGene: cellandgene.com/doc/legend-s…
Congrats to #client @nacuitypharma for the @US_FDA Fast Track designation of NPI-001 tablets for the treatment #RetinitisPigmentosa associated with Usher syndrome (#USH). Read more: piemagazine.org/fda-grants-f…
Hope for retinitis pigmentosa may come in a tablet form. #FDA grants Fast Track to Nacuity’s NPI-001, a potential game changer to combat oxidative stress and protect vision. Uncover the details here: piemagazine.org/fda-grants-f…
#RetinitisPigmentosa #PIEMagazine #MediaMICE
Biotech and pharma companies are increasingly seeking out alternative social media platforms. While awaiting the growth of alternative platforms, making accounts and securing handles are prudent first steps before determining how and if to engage. nytimes.com/2024/11/21/techn…
Despite being physically apart, this time of year is a special opportunity to connect the team. This year we hosted a virtual ugly holiday sweater party and contest. It’s been a wonderful year and we look forward to entering the new year with our outstanding team!
At #ASH24, #client @LegendBiotech presented new results from the Phase 3 study evaluating its BCMA-targeted #CART cell therapy for multiple myeloma and CEO Ying Huang discussed CARTITUDE-4 and the future of multiple myeloma treatment with @BiotechTV: biotechtv.com/post/legend-bi…
𝐀𝐒𝐇 𝟐𝟎𝟐𝟒: @LegendBiotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN
Full video: biotechtv.com/post/legend-bi…
Congrats to our #client Jupiter Bioventures and founders @NathanielEDavid and @nes047 on its launch! This new #biotech venture foundry raised $70M to advance 8-10 companies in #cancer and other diseases where cancer biology provides insight. endpts.com/jupiter-bioventur…
Congrats to our #client Atsena Therapeutics on its exclusive license agreement with Nippon Shinyaku Co., Ltd. to advance ATSN-101, a first-in-class ocular #GeneTherapy to treat the #InheritedRetinalDisease #LCA1, in the U.S. and Japan. atsenatx.com/press-release/n…
You never have a second chance to make a first impression. Company websites and social media profiles must be professional, consistent and up-to-date to make a good impression on investors.
Many early-stage companies make the mistake of DIYing their online presence, but a professional touch can be the key to capturing the attention and confidence of investors. Need tips on how to improve your online presence? Email us at [email protected] for a 30-minute chat.
Has your company recently secured a key grant or reached a significant milestone? Issuing a press release can bring your news directly to targeted media outlets, journalists and key stakeholders and provide meaningful context behind your company’s overall strategy. #PRtip
Congratulations to @LegendBiotech (#client) on its upcoming R&D facility. Philadelphia is a growing biotech community with a wealth talent coming out of academic institutions to tap into and Legend will be a great addition!
#LegendNews: We are excited to share plans to establish a new, state-of-the-art R&D facility in Philadelphia next year.
The new 31,000-square-foot site will advance our portfolio and expand our R&D capabilities as a global #CellTherapy leader.
Read more: globenewswire.com/en/news-re…
Congrats to #client Superluminal Medicines on the formation of its SAB. Superluminal Medicines is experiencing a critical period of growth and the addition of the inaugural SAB members is an exciting step. Read the announcement here ⬇️ globenewswire.com/en/news-re…
Our #client @NacuityPharma is developing its proprietary, GMP-grade #NACA tablets to target #oxidativestress causing #visionloss in patients with #UsherSyndrome. Learn more: nacuity.com
Finding treatments and cures for rare diseases like Usher syndrome is often limited by insufficient research and funding. Join us to spread awareness for #UshDay to help accelerate research and improve the lives of people experiencing #VisionLoss caused by #USH.
